Condition
B Cell Lymphomas
Total Trials
4
Recruiting
0
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Withdrawn1
Active Not Recruiting1
Completed1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02650414Phase 1Active Not Recruiting
CD22 Redirected Autologous T Cells for ALL
NCT02840110TerminatedPrimary
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
NCT03920631Phase 1WithdrawnPrimary
Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas
NCT01955668Phase 1Completed
AZD6738 First Time in Patient Multiple Ascending Dose Study
Showing all 4 trials